<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30391" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Valproate Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Ashish R.</given-names>
          </name>
          <aff>BJ Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashish Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30391.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Valproate toxicity results from an excessive accumulation of valproic acid in the body, often triggered by factors like high dosages, rapid dose adjustments, or interactions with other medications. Symptoms vary widely, including gastrointestinal distress symptoms such as nausea and vomiting, neurological manifestations like drowsiness, confusion, and, in severe cases, coma or fatality. Timely identification of risk factors and early symptom recognition is pivotal for intervening and mitigating adverse consequences. Treatment strategies involve a multifaceted approach, including supportive care to manage symptoms and specific interventions like L-carnitine therapy or hemodialysis to remove excess valproic acid from the bloodstream.</p>
        <p>Through this course, participants better understand valproate toxicity comprehensively, including proficient identification of risk factors, thorough patient assessment techniques, and implementing appropriate diagnostic and therapeutic measures. Additionally, collaborating with an interprofessional team is emphasized, as this enhances patient outcomes significantly by facilitating seamless communication and coordination across various healthcare disciplines. By leveraging the expertise and resources of diverse specialists, patient care&#x000a0;is optimized, ensuring timely and targeted interventions that improve safety and clinical effectiveness.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Screen patients for valproate toxicity, particularly hypoalbuminemic individuals or those exhibiting persistent symptoms despite normal total valproate levels.</p></list-item><list-item><p>Implement appropriate diagnostic and therapeutic measures for patients suspected of valproate toxicity, such as obtaining unbound valproate levels and initiating L-carnitine therapy or hemodialysis when indicated.</p></list-item><list-item><p>Differentiate between symptoms of valproate toxicity and other medical conditions to facilitate accurate diagnosis and timely intervention.</p></list-item><list-item><p>Collaborate with interprofessional teams to ensure comprehensive patient care, leveraging expertise from various specialties to optimize outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30391">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30391.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The valproate ion is the therapeutically active substance in valproic acid, sodium valproate, and divalproex.<xref ref-type="bibr" rid="article-30391.r1">[1]</xref>&#x000a0;Valproate is commonly used for generalized and partial seizures, bipolar disorders, schizoaffective disorders, neuropathic pain, and migraine prophylaxis.<xref ref-type="bibr" rid="article-30391.r2">[2]</xref>&#x000a0;Valproate toxicity can occur accidentally and intentionally. Toxicity is most likely to occur with dose ramping, in hypoalbuminemia, from drug-drug interactions, or in attempts to cause self-harm.&#x000a0;</p>
        <p>Patients with acute valproate overdose&#x000a0;typically experience hyperammonemia, encephalopathy, and hepatotoxicity. Symptoms consistent with severe valproate overdose include hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related&#x000a0;hyperammonemic&#x000a0;encephalopathy.</p>
      </sec>
      <sec id="article-30391.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Valproate toxicity commonly occurs when ramping up the dose to achieve&#x000a0;a therapeutic effect. Valproate toxicity may also occur when free or unbound drug levels become elevated. Elevated free drug concentrations are&#x000a0;common&#x000a0;in older patients and patients with hypoalbuminemia, and also in those who are pregnant, have renal dysfunction, liver disease, or in those who use medications that compete with valproate for albumin binding sites.<xref ref-type="bibr" rid="article-30391.r3">[3]</xref>&#x000a0;Additionally, patients who intentionally overdose on valproate during attempts of&#x000a0;self harm&#x000a0;experience varying degrees of valproate toxicity.<xref ref-type="bibr" rid="article-30391.r4">[4]</xref></p>
      </sec>
      <sec id="article-30391.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>According to the American Association of Poison Control Centers' National Poison Data System, cases of acute ingestion of valproate increased from 2717 in 1994 to 8705 in 2005.<xref ref-type="bibr" rid="article-30391.r5">[5]</xref>&#x000a0;More recently, cases of acute ingestion of valproate cases have stabilized. There were 3211 cases of acute valproate ingestion in 2010 and 2996 cases in 2018.<xref ref-type="bibr" rid="article-30391.r6">[6]</xref>&#x000a0;Children may be at particular risk for valproate toxicity, though it can occur in patients of all ages.<xref ref-type="bibr" rid="article-30391.r7">[7]</xref></p>
      </sec>
      <sec id="article-30391.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Patients with valproate toxicity commonly experience hyperammonemia, encephalopathy, and hepatotoxicity.<xref ref-type="bibr" rid="article-30391.r8">[8]</xref>&#x000a0;Valproate&#x000a0;decreases tissue carnitine levels, which results in microvesicular steatosis and hyperammonemia.<xref ref-type="bibr" rid="article-30391.r9">[9]</xref><xref ref-type="bibr" rid="article-30391.r10">[10]</xref>&#x000a0;Valproate-induced encephalopathy is typically related to the effects of hyperammonemia. However, valproate-induced cerebral edema&#x000a0;may also&#x000a0;be impacted&#x000a0;by altered valproate metabolism, which allows the presence of toxic drug metabolites to enter the brain.<xref ref-type="bibr" rid="article-30391.r8">[8]</xref><xref ref-type="bibr" rid="article-30391.r11">[11]</xref>&#x000a0;Valproate-induced hepatotoxicity is likely due to&#x000a0;inhibiting beta-oxidation of fatty acids, which results in mitochondrial injury.</p>
      </sec>
      <sec id="article-30391.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>In the United States, oral valproate&#x000a0;formulations include&#x000a0;valproic acid, sodium valproate, and divalproex. Valproic acid and sodium valproate are immediate-release formulations,&#x000a0;while divalproex&#x000a0;is formulated&#x000a0;as delayed- or extended-release. Valproate&#x000a0;is also formulated&#x000a0;for intravenous use as sodium valproate.<xref ref-type="bibr" rid="article-30391.r12">[12]</xref>&#x000a0;The liver metabolizes valproate primarily through&#x000a0;glucuronide conjugation and beta-oxidation. The average elimination half-life of valproate is approximately 11 hours.<xref ref-type="bibr" rid="article-30391.r13">[13]</xref>&#x000a0;However, the elimination&#x000a0;half-life of valproate can increase to 30 or more hours in the setting of acute overdose despite elimination via first-order kinetics.<xref ref-type="bibr" rid="article-30391.r14">[14]</xref>&#x000a0;In the setting of valproate toxicity, a greater degree of omega-oxidation occurs in the liver, which increases the risk of hepatotoxicity, cerebral edema, and hyperammonemia.<xref ref-type="bibr" rid="article-30391.r11">[11]</xref>&#x000a0;Cytochrome P (CYP)2C9 and CYP2A6 enzymes also play a role in valproate metabolism. Results from a recently published meta-analysis showed that patients with&#x000a0;CYP2C9*3 and CYP2A6*4 genotype variants had higher serum valproate concentrations than patients without.<xref ref-type="bibr" rid="article-30391.r15">[15]</xref></p>
        <p>Very little valproate&#x000a0;is excreted&#x000a0;in the urine as an unchanged drug. Aspirin increases free serum valproate levels by competing for plasma protein binding sites. Hypoalbuminemia, a condition common in patients who are older and in those with liver disease, also increases free serum valproate&#x000a0;levels. Because total valproate serum levels may remain constant despite alterations in protein binding, measuring free or unbound serum levels is best practice in the setting of valproate toxicity.<xref ref-type="bibr" rid="article-30391.r16">[16]</xref></p>
      </sec>
      <sec id="article-30391.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>When assessing a patient with suspected valproate toxicity, clinicians should&#x000a0;ascertain the specific time of valproate ingestion, valproate formulation, the amount of valproate ingested, other possible coingestants (eg, acetaminophen or alcohol), and a list of all of the patient's prior psychiatric or medical problems. Patients with acute ingestion of 200 mg/kg of valproate or serum valproate concentrations&#x000a0;of 180 mg/L or greater often&#x000a0;experience&#x000a0;central nervous system dysfunction. Manifestations of central nervous system dysfunction include tremors, agitation, miosis, and other focal neurological deficits. Patients who experience valproate-related hyperammonemic encephalopathy may experience confusion, seizures, and lethargy, which&#x000a0;can progress to stupor, coma, and death.<xref ref-type="bibr" rid="article-30391.r17">[17]</xref><xref ref-type="bibr" rid="article-30391.r18">[18]</xref>&#x000a0;Additionally, patients with valproate toxicity may experience respiratory depression, hypotension, and tachycardia.&#x000a0;Gastrointestinal symptoms consistent with valproate toxicity include vomiting, diarrhea, and abdominal pain.<xref ref-type="bibr" rid="article-30391.r11">[11]</xref>&#x000a0;</p>
        <p>Interestingly, the dermatohistopathology of valproate toxicity has&#x000a0;been consistent&#x000a0;with cases of hypersensitivity vasculitis and psoriasiform eruption. Patients&#x000a0;on chronic valproate therapy&#x000a0;may also exhibit symptoms consistent&#x000a0;with alopecia due to telogen effluvium, including diffuse hair loss, thinning, and graying.<xref ref-type="bibr" rid="article-30391.r19">[19]</xref>&#x000a0;Valproate is also a potential teratogen. Fetal exposure&#x000a0;to valproate during pregnancy&#x000a0;can result in a wide range of congenital malformations, including&#x000a0;spina bifida, anencephaly, craniofacial abnormalities, and genitourinary defects.<xref ref-type="bibr" rid="article-30391.r20">[20]</xref></p>
      </sec>
      <sec id="article-30391.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Therapeutic serum concentrations of valproate usually range from 50 to 100 mg/L. Valproate levels should be obtained every 2&#x000a0;to 4 hours for patients with suspected valproate toxicity and until the serum valproate level starts declining. A steady decline in the level suggests a peak serum level has&#x000a0;been reached.<xref ref-type="bibr" rid="article-30391.r21">[21]</xref>&#x000a0;Unbound valproate levels are an assessment tool in patients who are&#x000a0;hypoalbuminemic,&#x000a0;or when signs of valproate toxicity are present despite low or normal total valproate levels.<xref ref-type="bibr" rid="article-30391.r16">[16]</xref></p>
        <p>Other&#x000a0;important&#x000a0;laboratory&#x000a0;tests to order for patients with suspected valproate toxicity&#x000a0;include a complete blood count with differential. If the patient is experiencing valproate toxicity, thrombocytopenia, and decreased granulocyte counts may be present. Additionally, a comprehensive metabolic panel is helpful to assess the patient for hypoglycemia, hepatotoxicity, electrolyte abnormalities, and acid-base disorders. Blood ammonia levels should&#x000a0;be studied&#x000a0;for patients experiencing encephalopathy.&#x000a0;Toxicologic screening for&#x000a0;coingestants, including other anticonvulsants, aspirin, and&#x000a0;acetaminophen&#x000a0;should also considered.&#x000a0;A pregnancy test should&#x000a0;be ordered&#x000a0;for women of childbearing age.<xref ref-type="bibr" rid="article-30391.r21">[21]</xref></p>
        <p>Other tests to&#x000a0;consider include&#x000a0;a<bold>&#x000a0;</bold>12-lead echocardiogram that shows an atrioventricular conduction block.<xref ref-type="bibr" rid="article-30391.r22">[22]</xref>&#x000a0;Sometimes, severe valproate toxicity is associated with atrial tachycardia.<xref ref-type="bibr" rid="article-30391.r23">[23]</xref>&#x000a0;A computed tomography scan of the head&#x000a0;is necessary when patients present with signs of focal neurological deficits, profound central nervous system depression, or suspicion of cerebral edema.<xref ref-type="bibr" rid="article-30391.r19">[19]</xref></p>
      </sec>
      <sec id="article-30391.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Initial therapy for patients with valproate toxicity should focus on medical stabilization and resuscitation. Specifically, initial interventions should focus on maintaining the airway, breathing, and circulation.&#x000a0;Patients with severe respiratory depression may require endotracheal intubation and mechanical ventilation.&#x000a0;Intravenous access may be needed to provide intravenous fluid&#x000a0;and vasopressors for patients presenting with hypotension.&#x000a0;Benzodiazepines should&#x000a0;be administered&#x000a0;if there is a seizure due to valproate toxicity.<xref ref-type="bibr" rid="article-30391.r24">[24]</xref>&#x000a0;</p>
        <p>Other&#x000a0;interventions to consider early for patients with valproate toxicity are gastrointestinal decontamination and lavage. If the patient presents within 2 hours of a valproate overdose, activated charcoal may&#x000a0;be used&#x000a0;for gastrointestinal decontamination. Valproate is available in enteric-coated and extended-release formulations, which have slow absorption. Administration of activated charcoal&#x000a0;may&#x000a0;be considered&#x000a0;beyond 2 hours from ingestion for&#x000a0;patients who have taken enteric-coated and extended-release valproate formulations.<xref ref-type="bibr" rid="article-30391.r25">[25]</xref>&#x000a0;The dose of activated charcoal is 1 g/kg of body weight. If the patient cannot&#x000a0;swallow reliably, the administration of activated charcoal should&#x000a0;be withheld. Gastric lavage may also&#x000a0;be considered&#x000a0;to eliminate valproate from the digestive tract. Food and Drug Administration guidelines indicate that gastric lavage treatment may be effective up to 10 or 12 hours after drug intake.<xref ref-type="bibr" rid="article-30391.r26">[26]</xref>&#x000a0;</p>
        <p>After initial stabilization, it is prudent to consider the use of L-carnitine for patients presenting with an acute overdose of valproate and altered mental status. L-carnitine should be administered intravenously with a loading dose of 100 mg/kg, followed by 50 mg/kg intravenously every 8 hours. Serum ammonia levels should be simultaneously measured, and when serum ammonia levels start decreasing, L-carnitine therapy can&#x000a0;be discontinued.<xref ref-type="bibr" rid="article-30391.r27">[27]</xref>&#x000a0;In the pediatric population, resulting evidence from a few case reports shows that carnitine may&#x000a0;alter the generation of potentially toxic metabolites, but it may not translate into improved clinical prognosis.<xref ref-type="bibr" rid="article-30391.r28">[28]</xref>&#x000a0;Interestingly, the mu-opioid receptor antagonist naloxone may reverse the central nervous system&#x000a0;depression in&#x000a0;some cases of&#x000a0;valproate poisoning.<xref ref-type="bibr" rid="article-30391.r29">[29]</xref><xref ref-type="bibr" rid="article-30391.r30">[30]</xref>&#x000a0;Naloxone may also be&#x000a0;useful&#x000a0;for chronic valproate intoxication.<xref ref-type="bibr" rid="article-30391.r31">[31]</xref></p>
        <p>Hemodialysis&#x000a0;is indicated&#x000a0;for serum valproate concentrations&#x000a0;greater&#x000a0;than 1300 mg/L and in patients experiencing shock or cerebral edema.&#x000a0;Hemodialysis can&#x000a0;greatly&#x000a0;reduce&#x000a0;the elimination half-life of valproate. In one case study, hemodialysis decreased&#x000a0;the half-life of&#x000a0;valproate from 13 hours to 1.7 hours. Additionally, hemodialysis contributed to significant clinical improvement for the patient within 4 hours of treatment.&#x000a0;Intermittent hemodialysis is the preferred technique for patients experiencing valproate toxicity, although continuous renal replacement therapy is an acceptable alternative if the patient cannot tolerate intermittent hemodialysis. Hemodialysis treatment can&#x000a0;be discontinued&#x000a0;if the serum valproate&#x000a0;concentration&#x000a0;drops below&#x000a0;100 mg/L and the patient&#x000a0;shows signs of clinical improvement, including normotension, improved mental status,&#x000a0;pH normalization,&#x000a0;and resolution of electrolyte abnormalities.<xref ref-type="bibr" rid="article-30391.r32">[32]</xref></p>
      </sec>
      <sec id="article-30391.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Symptoms of valproate toxicity overlap with many conditions. Thus, a detailed history, physical examination, laboratory evaluation, and cerebral imaging are required to diagnose valproate toxicity.<xref ref-type="bibr" rid="article-30391.r33">[33]</xref>&#x000a0;The most common symptoms of valproate toxicity are altered mental status and central nervous system depression, which can be due to a wide range of conditions. Suspicion of meningitis should arise when a patient presents with fever and neck stiffness accompanied by altered mental status.&#x000a0;</p>
        <p>Herpes simplex virus-1 encephalitis&#x000a0;typically shows temporal lobe involvement in magnetic resonance images. Additionally, cranial neoplasm, intracranial hemorrhage, hydrocephalus, and traumatic brain injury should&#x000a0;be ruled out&#x000a0;as the cause of these symptoms.&#x000a0;Valproate-induced tremors occur in about 10% of patients and require differentiation from essential tremors or tremors associated with Parkinson disease.&#x000a0;</p>
        <p>A comprehensive metabolic panel should&#x000a0;be ordered&#x000a0;to search for metabolic derangements,&#x000a0;including&#x000a0;hypoglycemia and hypernatremia. As serum ammonia is frequently elevated with valproate poisoning, disorders of urea cycle disorders and hepatic encephalopathy should merit consideration. Finally, other causes of anion gap metabolic acidosis should&#x000a0;be investigated. Common causes of anion gap metabolic acidosis include uremia, methanol poisoning, diabetic ketoacidosis, and lactic acidosis.</p>
      </sec>
      <sec id="article-30391.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for patients with valproate toxicity will depend on the total amount of valproate ingested, the opportunity to implement decontamination and elimination strategies, and the supportive care given. Severe ingestions may resolve without any sequelae after aggressive decontamination, elimination, and adequate supportive caIn one observational, retrospective study involving 316 patients, the&#x000a0;prognosis of patients with acute valproate toxicity was good with supportive care alone. According to the multivariate analysis within the study, a coma during the initial presentation&#x000a0;was associated&#x000a0;with a poor prognosis. Other poor prognostic factors include advanced age, metabolic derangements, and ingesting large amounts of valproate.<xref ref-type="bibr" rid="article-30391.r34">[34]</xref></p>
      </sec>
      <sec id="article-30391.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Acute valproate toxicity can result in dose-related and reversible hepatotoxicity. Usually, ceasing the drug therapy results in the normalization of liver function abnormalities, but fulminant&#x000a0;hepatic failure and death have&#x000a0;been reported&#x000a0;with valproate toxicity.<xref ref-type="bibr" rid="article-30391.r35">[35]</xref><xref ref-type="bibr" rid="article-30391.r36">[36]</xref>&#x000a0;Concerningly, liver transplants in children with valproate-induced acute hepatic failure have reduced survival rates compared to liver transplants from other causes of drug-induced liver injury.<xref ref-type="bibr" rid="article-30391.r37">[37]</xref>&#x000a0;Cerebral edema may lead to herniation, prolonged central nervous system depression, and coma.<xref ref-type="bibr" rid="article-30391.r11">[11]</xref><xref ref-type="bibr" rid="article-30391.r14">[14]</xref>&#x000a0;Valproate-related hyperammonemic encephalopathy can lead to&#x000a0;confusion, lethargy, and increased seizure frequency. If severe valproate toxicity is untreated, death may result.<xref ref-type="bibr" rid="article-30391.r38">[38]</xref><xref ref-type="bibr" rid="article-30391.r39">[39]</xref></p>
      </sec>
      <sec id="article-30391.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>A poison control center should always&#x000a0;be consulted&#x000a0;when a patient presents with valproate toxicity. Contact with a poison control center is critical when the diagnosis of valproate toxicity is unclear or if the patient is critically ill.&#x000a0;A&#x000a0;nephrology consultation and consideration for hemodialysis&#x000a0;is recommended&#x000a0;when valproate toxicity&#x000a0;is accompanied&#x000a0;by cerebral edema or shock or if the serum valproate concentration is more than 1300 mg/L.<xref ref-type="bibr" rid="article-30391.r32">[32]</xref>&#x000a0;All patients with intentional valproate overdose also require consultation with a psychiatrist.</p>
      </sec>
      <sec id="article-30391.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>On discharge, the patient&#x000a0;should&#x000a0;receive counsel that&#x000a0;liver problems can happen with valproate overdose, which can be fatal. Parents need to know that children&#x000a0;under&#x000a0;2&#x000a0;years old are at higher risk of deadly liver problems, including&#x000a0;Alpers&#x02013;Huttenlocher syndrome.<xref ref-type="bibr" rid="article-30391.r37">[37]</xref>&#x000a0;Pregnant&#x000a0;women&#x000a0;should be educated that valproate may cause severe congenital disabilities, including spina bifida and neurodevelopmental disorders, and that contraception should&#x000a0;be used&#x000a0;if women are sexually active while taking valproate.<xref ref-type="bibr" rid="article-30391.r20">[20]</xref>&#x000a0;Patients should also be informed of the risk of pancreatitis with long-term therapy. Specifically, patients should&#x000a0;be advised&#x000a0;to immediately contact their clinician or an emergency department if they develop symptoms such as acute abdominal pain, nausea, vomiting, or fever.<xref ref-type="bibr" rid="article-30391.r40">[40]</xref></p>
      </sec>
      <sec id="article-30391.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>To&#x000a0;improve&#x000a0;patient-centered care and outcomes related to valproate toxicity, physicians, advanced practice providers, nurses, pharmacists, and other health professionals must develop comprehensive skills and strategies. Physicians and advanced practice providers should identify risk factors,&#x000a0;apply their expertise in assessing patients for signs of overdose, implement appropriate interventions, and coordinate multidisciplinary care.</p>
        <p>Nurses are crucial in monitoring patients and providing supportive care during stabilization and resuscitation. Pharmacists should ensure accurate medication management and dosing adjustments.&#x000a0;Effective interprofessional communication among team members is essential for sharing critical information, interpreting laboratory results, and making timely decisions regarding treatment modalities like L-carnitine and hemodialysis. Care coordination efforts should prioritize patient safety and optimize team performance, ultimately improving outcomes for patients experiencing valproate toxicity.</p>
      </sec>
      <sec id="article-30391.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30391">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/valproate-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30391">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30391/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30391">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30391.s17">
        <title>References</title>
        <ref id="article-30391.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delage</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Palayer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Etain</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hagenimana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blaise</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chouchana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Besson</surname>
                <given-names>VC</given-names>
              </name>
            </person-group>
            <article-title>Valproate, divalproex, valpromide: Are the differences in indications justified?</article-title>
            <source>Biomed Pharmacother</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>158</volume>
            <fpage>114051</fpage>
            <pub-id pub-id-type="pmid">36521249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;scher</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.</article-title>
            <source>CNS Drugs</source>
            <year>2002</year>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>669</fpage>
            <page-range>669-94</page-range>
            <pub-id pub-id-type="pmid">12269861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smits</surname>
                <given-names>JEMP</given-names>
              </name>
              <name>
                <surname>Wallenburg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Spanje</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Luin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marijnissen</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Valproate Intoxication in a Patient With Blood Valproate Levels Within Therapeutic Range.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>e413</fpage>
            <page-range>e413-e414</page-range>
            <pub-id pub-id-type="pmid">28448701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrey</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Geulayov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bankhead</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gunnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hawton</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Relative toxicity of mood stabilisers and antipsychotics: case fatality and fatal toxicity associated with self-poisoning.</article-title>
            <source>BMC Psychiatry</source>
            <year>2018</year>
            <month>Dec</month>
            <day>27</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>399</fpage>
            <pub-id pub-id-type="pmid">30587176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bronstein</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cantilena</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rumack</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>10</issue>
            <fpage>910</fpage>
            <page-range>910-41</page-range>
            <pub-id pub-id-type="pmid">22165864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Beuhler</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rivers</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hashem</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>12</issue>
            <fpage>1220</fpage>
            <page-range>1220-1413</page-range>
            <pub-id pub-id-type="pmid">31752545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell-Jackson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Tredger</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity to sodium valproate: a review.</article-title>
            <source>Gut</source>
            <year>1984</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>673</fpage>
            <page-range>673-81</page-range>
            <pub-id pub-id-type="pmid">6428980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rupasinghe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jasinarachchi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Progressive encephalopathy with cerebral oedema and infarctions associated with valproate and diazepam overdose.</article-title>
            <source>J Clin Neurosci</source>
            <year>2011</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>710</fpage>
            <page-range>710-1</page-range>
            <pub-id pub-id-type="pmid">21349718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <chapter-title>Valproate</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">31643607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schumacher</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Mechanistic review of drug-induced steatohepatitis.</article-title>
            <source>Toxicol Appl Pharmacol</source>
            <year>2015</year>
            <month>Nov</month>
            <day>15</day>
            <volume>289</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-7</page-range>
            <pub-id pub-id-type="pmid">26344000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dupuis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Lichtman</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites.</article-title>
            <source>Drug Saf</source>
            <year>1990</year>
            <season>Jan-Feb</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-71</page-range>
            <pub-id pub-id-type="pmid">2106903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Citrome</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Valproate: do formulations matter?</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>457; author reply 458</fpage>
            <pub-id pub-id-type="pmid">18613865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chadwick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Concentration-effect relationships of valproic acid.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1985</year>
            <season>Mar-Apr</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-63</page-range>
            <pub-id pub-id-type="pmid">3922659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gram</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bentsen</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Valproate: an updated review.</article-title>
            <source>Acta Neurol Scand</source>
            <year>1985</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-39</page-range>
            <pub-id pub-id-type="pmid">2931939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoon</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gwak</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>76</volume>
            <issue>8</issue>
            <fpage>1053</fpage>
            <page-range>1053-1058</page-range>
            <pub-id pub-id-type="pmid">32385545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dor&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>San Juan</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Frenette</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical Importance of Monitoring Unbound Valproic Acid Concentration in Patients with Hypoalbuminemia.</article-title>
            <source>Pharmacotherapy</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>900</fpage>
            <page-range>900-907</page-range>
            <pub-id pub-id-type="pmid">28574586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoo</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Leyland</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Cerebral edema following acute sodium valproate overdose.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1992</year>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-14</page-range>
            <pub-id pub-id-type="pmid">1588670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dealberto</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>330</fpage>
            <page-range>330-7</page-range>
            <pub-id pub-id-type="pmid">17917551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chateauvieux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morceau</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dicato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diederich</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Molecular and therapeutic potential and toxicity of valproic acid.</article-title>
            <source>J Biomed Biotechnol</source>
            <year>2010</year>
            <volume>2010</volume>
            <pub-id pub-id-type="pmid">20798865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alsdorf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wyszynski</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Teratogenicity of sodium valproate.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-53</page-range>
            <pub-id pub-id-type="pmid">15794725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mortensen</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hartmann-Andersen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Husted</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Acute valproate intoxication: biochemical investigations and hemodialysis treatment.</article-title>
            <source>Int J Clin Pharmacol Ther Toxicol</source>
            <year>1983</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>64</fpage>
            <page-range>64-8</page-range>
            <pub-id pub-id-type="pmid">6404845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davutoglu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Neyal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altunbas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Valproic Acid as a Cause of Transient Atrio-Ventricular Conduction Block Episodes.</article-title>
            <source>J Atr Fibrillation</source>
            <year>2017</year>
            <season>Feb-Mar</season>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>1520</fpage>
            <pub-id pub-id-type="pmid">29250271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuhlmann</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Limbach</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Lindinger</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Severe valproic acid intoxication is associated with atrial tachycardia: secondary detoxication by hemoperfusion.</article-title>
            <source>Klin Padiatr</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>217</volume>
            <issue>2</issue>
            <fpage>82</fpage>
            <page-range>82-5</page-range>
            <pub-id pub-id-type="pmid">15770579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sztajnkrycer</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Valproic acid toxicity: overview and management.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2002</year>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>789</fpage>
            <page-range>789-801</page-range>
            <pub-id pub-id-type="pmid">12475192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aaron</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1996</year>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>335</fpage>
            <page-range>335-41</page-range>
            <pub-id pub-id-type="pmid">8667473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Rescue strategies for valproic acid overdose poisoning: Case series and literature review.</article-title>
            <source>Clin Case Rep</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>e8367</fpage>
            <pub-id pub-id-type="pmid">38161627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perrott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Zed</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>L-carnitine for acute valproic acid overdose: a systematic review of published cases.</article-title>
            <source>Ann Pharmacother</source>
            <year>2010</year>
            <season>Jul-Aug</season>
            <volume>44</volume>
            <issue>7-8</issue>
            <fpage>1287</fpage>
            <page-range>1287-93</page-range>
            <pub-id pub-id-type="pmid">20587742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russell</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Carnitine as an antidote for acute valproate toxicity in children.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>206</fpage>
            <page-range>206-10</page-range>
            <pub-id pub-id-type="pmid">17496767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alberto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Popiel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hryhorczuk</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Central nervous system manifestations of a valproic acid overdose responsive to naloxone.</article-title>
            <source>Ann Emerg Med</source>
            <year>1989</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>889</fpage>
            <page-range>889-91</page-range>
            <pub-id pub-id-type="pmid">2502939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montero</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Naloxone in the reversal of coma induced by sodium valproate.</article-title>
            <source>Ann Emerg Med</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>357</fpage>
            <page-range>357-8</page-range>
            <pub-id pub-id-type="pmid">10036355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thanacoody</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Chronic valproic acid intoxication: reversal by naloxone.</article-title>
            <source>Emerg Med J</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>9</issue>
            <fpage>677</fpage>
            <page-range>677-8</page-range>
            <pub-id pub-id-type="pmid">17711961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghannoum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lalibert&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nolin</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>MacTier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <collab>EXTRIP Workgroup</collab>
            </person-group>
            <article-title>Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>454</fpage>
            <page-range>454-65</page-range>
            <pub-id pub-id-type="pmid">25950372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murty</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antiepileptic Overdose.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>Suppl 4</issue>
            <fpage>S290</fpage>
            <page-range>S290-S295</page-range>
            <pub-id pub-id-type="pmid">32021007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shadnia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amiri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hassanian-Moghaddam</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rezai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vasei</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ghodrati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zamani</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Favorable results after conservative management of 316 valproate intoxicated patients.</article-title>
            <source>J Res Med Sci</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>656</fpage>
            <page-range>656-61</page-range>
            <pub-id pub-id-type="pmid">26622254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bryant</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Dreifuss</surname>
                <given-names>FE</given-names>
              </name>
            </person-group>
            <article-title>Valproic acid hepatic fatalities. III. U.S. experience since 1986.</article-title>
            <source>Neurology</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>465</fpage>
            <page-range>465-9</page-range>
            <pub-id pub-id-type="pmid">8614514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Star</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Choonara</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>e108970</fpage>
            <pub-id pub-id-type="pmid">25302991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mindikoglu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Magder</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Ozolek</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mazariegos</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Shneider</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.</article-title>
            <source>J Pediatr</source>
            <year>2011</year>
            <month>May</month>
            <volume>158</volume>
            <issue>5</issue>
            <fpage>802</fpage>
            <page-range>802-7</page-range>
            <pub-id pub-id-type="pmid">21167499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verrotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trotta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morgese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chiarelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Valproate-induced hyperammonemic encephalopathy.</article-title>
            <source>Metab Brain Dis</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>367</fpage>
            <page-range>367-73</page-range>
            <pub-id pub-id-type="pmid">12602513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duarte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Macias</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coria</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Claver&#x000ed;a</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Valproate-induced coma: case report and literature review.</article-title>
            <source>Ann Pharmacother</source>
            <year>1993</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>582</fpage>
            <page-range>582-3</page-range>
            <pub-id pub-id-type="pmid">8347908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30391.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perucca</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.</article-title>
            <source>CNS Drugs</source>
            <year>2002</year>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>695</fpage>
            <page-range>695-714</page-range>
            <pub-id pub-id-type="pmid">12269862</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
